Literature DB >> 8033354

Serum carnosinase activities in central nervous system disorders.

W S Wassif1, R A Sherwood, A Amir, B Idowu, B Summers, N Leigh, T J Peters.   

Abstract

Serum carnosinase activity was assayed in five groups of patients with neurological disorders. Enzyme activities in patients with idiopathic epilepsy (mean +/- S.E.M., 148 +/- 11 nmol/ml per min) and motor neurone disease (155 +/- 15 nmol/ml per min) were similar to the control group (161 +/- 7 nmol/ml per min). Reduced serum carnosinase activity was observed in patients with Parkinson's disease (109 +/- 11 nmol/ml per min, P < 0.005), multiple sclerosis (82.5 +/- 10.0 nmol/ml per min, P < 0.005) and patients following a cerebrovascular accident (74.6 +/- 5.4 nmol/ml per min, P < 0.001) compared with the control group. Carnosinase activity, 5-10% of that found in serum, was detected in CSF samples. The cause of reduced serum carnosinase activities in central nervous system disorders is unclear, although anoxic damage to carnosinase-producing cells or disruption of the blood-brain barrier may be responsible.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8033354     DOI: 10.1016/0009-8981(94)90027-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

Review 1.  Antioxidant and Neuroprotective Effects of Carnosine: Therapeutic Implications in Neurodegenerative Diseases.

Authors:  Cristina Solana-Manrique; Francisco José Sanz; Guillermo Martínez-Carrión; Nuria Paricio
Journal:  Antioxidants (Basel)       Date:  2022-04-26

2.  Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis.

Authors:  Poonam Gautam; Sudha C Nair; Manoj Kumar Gupta; Rakesh Sharma; Ravindra Varma Polisetty; Megha S Uppin; Challa Sundaram; Aneel K Puligopu; Praveen Ankathi; Aniruddh K Purohit; Giriraj R Chandak; H C Harsha; Ravi Sirdeshmukh
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

3.  Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis.

Authors:  Ester Cantó; Mar Tintoré; Luisa Maria Villar; Eva Borrás; Jose Carlos Alvarez-Cermeño; Cristina Chiva; Eduard Sabidó; Alex Rovira; Xavier Montalban; Manuel Comabella
Journal:  J Neuroinflammation       Date:  2014-11-13       Impact factor: 8.322

4.  Chromosomal microarray analysis in a cohort of underrepresented population identifies SERINC2 as a novel candidate gene for autism spectrum disorder.

Authors:  Areerat Hnoonual; Weerin Thammachote; Thipwimol Tim-Aroon; Kitiwan Rojnueangnit; Tippawan Hansakunachai; Tasanawat Sombuntham; Rawiwan Roongpraiwan; Juthamas Worachotekamjorn; Jariya Chuthapisith; Suthat Fucharoen; Duangrurdee Wattanasirichaigoon; Nichara Ruangdaraganon; Pornprot Limprasert; Natini Jinawath
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

5.  Altered CSF Proteomic Profiling of Paediatric Acute Lymphocytic Leukemia Patients with CNS Infiltration.

Authors:  Fei Mo; Xuelei Ma; Xiaobei Liu; Ruofan Zhou; Yunuo Zhao; Hui Zhou
Journal:  J Oncol       Date:  2019-05-02       Impact factor: 4.375

6.  Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.

Authors:  Eboni I Lance; Lisa M Faulcon; Zongming Fu; Jun Yang; Donna Whyte-Stewart; John J Strouse; Emily Barron-Casella; Kimberly Jones; Jennifer E Van Eyk; James F Casella; Allen D Everett
Journal:  Proteomics Clin Appl       Date:  2021-05-24       Impact factor: 3.603

7.  Multi-target action of β-alanine protects cerebellar tissue from ischemic damage.

Authors:  Olga Kopach; Dmitri A Rusakov; Sergiy Sylantyev
Journal:  Cell Death Dis       Date:  2022-08-29       Impact factor: 9.685

8.  Brain type carnosinase in dementia: a pilot study.

Authors:  Cynthia M Balion; Carolyn Benson; Parminder S Raina; Alexandra Papaioannou; Christopher Patterson; Afisi S Ismaila
Journal:  BMC Neurol       Date:  2007-11-05       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.